Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nilotinib plus pegylated interferon alfa-2b in chronic myeloid leukemia with persistent molecular residual disease after long-term imatinib
2012-004321-25Phase 2Terminated
- Sponsor
- VU University Medical Center
- Start
- Feb 2013
- Modality
- Small Molecules, Cytokines & Interferons → Recombinant Proteins and Enzymes, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nilotinib and peginterferon alfa-2b in chronic myelogenous leukemia (CML), sponsored by VU University Medical Center. Started Feb 2013; status: terminated.
02
Drugs
nilotinibpeginterferon alfa-2b
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2012-004321-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-004321-25.